Tosoh G8 now connects to Sysmex XN-9000, XN-9100 systems

written by CAP TODAY
January 16, 2024

January 2024—Tosoh Bioscience has entered into an agreement with Sysmex America in which its HLC-723G8 automated glycohemoglobin analyzers can be connected to Sysmex XN-9000 and XN-9100 automated hematology systems in the United States, Latin America, and Canada. With this agreement, Tosoh says it aims to expand its HbA1c offering to the high-volume testing market and further automate hemoglobin A1c testing.

©2026 CAP TODAY, all rights reserved.

Roche launches Elecsys HBeAg quant in CE markets

written by CAP TODAY
January 16, 2024

January 2024—Roche launched the Elecsys HBeAg quant, an immunoassay for the in vitro qualitative and quantitative determination of hepatitis B e antigen in human serum and plasma. In conjunction with other laboratory results and clinical information, HBeAg quantification may be used as an aid in the diagnosis and monitoring of patients with hepatitis B viral infection. It is for use on Cobas e analyzers in countries that accept the CE mark.

©2026 CAP TODAY, all rights reserved.

FDA clears QuidelOrtho Savanna PCR platform and HSV 1+2/VZV assay

written by CAP TODAY
January 16, 2024

January 2024—QuidelOrtho has received FDA 510(k) clearance for its Savanna PCR platform and Savanna HSV 1+2/VZV in vitro diagnostic test for the detection and differentiation of herpes simplex virus types 1 and 2 and varicella zoster virus nucleic acids isolated and purified from swabs obtained from cutaneous or mucocutaneous lesion specimens from symptomatic patients.

©2026 CAP TODAY, all rights reserved.

Ad Astra QScout hematology analyzer gets 510(k) clearance

written by CAP TODAY
January 16, 2024

January 2024—Ad Astra Diagnostics has received 510(k) clearance from the FDA for its QScout rapid-result hematology system. The analyzer provides point-of-care white blood cell counts and a neutrophil-to-lymphocyte ratio and differentiates the number and percent of five types of mature WBCs as well as immature granulocytes. To run the test, whole blood is added to a QScout rapid leukocyte differential test, which contains a dried reagent that stains cells. When the test is inserted in the QScout analyzer, an optical system takes images and an algorithm identifies the cells in real time. Results are displayed in about two minutes.

©2026 CAP TODAY, all rights reserved.

BioMérieux acquires software company Lumed

written by CAP TODAY
January 16, 2024

Jan. 11, 2024—BioMérieux has acquired the entire share capital of software company Lumed, increasing its stake from 16 to 100 percent.

©2026 CAP TODAY, all rights reserved.

Horiba Medical launches next-gen HELO hematology solution

written by CAP TODAY
January 16, 2024

Jan. 9, 2024—Horiba Medical has launched the CE-IVDR-approved HELO 2.0 high-throughput automated hematology platform.

©2026 CAP TODAY, all rights reserved.

New chapter in digital pathology

written by CAP TODAY
January 16, 2024

Jan. 8, 2024—Advancements in whole slide imaging, integration of AI, and global collaboration networks are three areas the new president of the Digital Pathology Association highlighted in his first communication with DPA members this year.

©2026 CAP TODAY, all rights reserved.

Sekisui, Aptitude partner to provide POC COVID test

written by CAP TODAY
January 16, 2024

Jan. 4, 2024—Sekisui Diagnostics formalized an exclusive distribution agreement with Aptitude Medical Systems to sell the Aptitude Metrix COVID-19 test in the United States.

©2026 CAP TODAY, all rights reserved.

FormaPath, UB CAT announce clinical R&D

collaboration

written by CAP TODAY
January 16, 2024

Jan. 4, 2024—FormaPath and the University at Buffalo Center for Advanced Technology in Big Data and Health Sciences (UB CAT) announced their collaboration to further test and develop FormaPath's AdiPress, an automated lymph node dissection device.

FormaPath and John Tomaszewski, MD, SUNY distinguished professor and the Peter A. Nickerson, PhD, Professor and Chair, Department of Pathology and Anatomical Sciences, Jacobs School of Medicine and Biomedical Sciences at UB, will use AdiPress to conduct comprehensive analyses of tissue specimens to identify and create lymph node–rich samples. This work will lead to the creation of a digital lymph node database, which will allow FormaPath to explore computational methods, including AI, that identify and analyze lymph nodes with metastatic disease.

UB CAT advances university-industry collaboration to drive the development of new technologies and grow life and health sciences businesses in New York State. The program is managed by the University at Buffalo Business and Entrepreneur Partnerships and funded by Empire State Development's Division of Science, Technology, and Innovation.

CAP TODAY
Pathology • Laboratory Medicine • Laboratory Management

©2026 CAP TODAY, all rights reserved.

Roche to acquire LumiraDx's POC technology

written by CAP TODAY
January 16, 2024

Jan. 2, 2024—Roche announced it has entered into a definitive agreement to acquire LumiraDx's point-of-care technology platform business, which offers a range of immunoassay and clinical chemistry tests that can be stored at room temperature.

CAP TODAY
Pathology • Laboratory Medicine • Laboratory Management

©2026 CAP TODAY, all rights reserved.